Vaxart Inc

NASDAQ:VXRT 4:00:00 PM EDT

0.45

-0.04 (-8.60%)

: $0.48 +0.03 (+6.86%)

Market Cap (Intraday)	94.32M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$2.03 Million
Adjusted EPS	-$0.09

See more estimates

10-Day MA	$0.51
50-Day MA	$0.46
200-Day MA	$0.61

See more pivots

Vaxart Inc Stock, NASDAQ:VXRT

170 Harbor Way, Suite 300, South San Francisco, California 94080

United States of America

Phone: +1.650.550.3500

Number of Employees: 125

http://www.vaxart.com

Description

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.